Opus Genetics (NASDAQ:IRD – Get Free Report) and Applied Therapeutics (NASDAQ:APLT – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.
Institutional and Insider Ownership
15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Opus Genetics and Applied Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Opus Genetics | 1 | 1 | 15 | 1 | 2.89 |
| Applied Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Profitability
This table compares Opus Genetics and Applied Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Opus Genetics | -1,091.82% | -338.88% | -150.13% |
| Applied Therapeutics | N/A | -340.84% | -175.00% |
Risk and Volatility
Opus Genetics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500.
Valuation & Earnings
This table compares Opus Genetics and Applied Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Opus Genetics | $14.20 million | 32.48 | -$49.59 million | ($1.35) | -4.13 |
| Applied Therapeutics | $1.00 million | 15.86 | -$105.62 million | ($0.10) | -1.03 |
Opus Genetics has higher revenue and earnings than Applied Therapeutics. Opus Genetics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Opus Genetics beats Applied Therapeutics on 9 of the 15 factors compared between the two stocks.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
About Applied Therapeutics
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
